|
|
|
|
|
Highlights from the 2023 Society of Urologic Oncology 24th Annual Meeting
|
|
|
|
|
| Grade and Volume Progression and Its Association with the Decipher Genomic Classifier Using Patients Enrolled in a Prospective Active Surveillance Protocol
|
| Archan Khandekar, MD
|
| Archan Khandekar discusses the association between grade and volume progression and the Decipher genomic classifier in prostate cancer patients on active surveillance, using data from the Miami Active Surveillance Trial (MAST). The study, based on 224 baseline samples, reveals that the Decipher score has a stronger correlation with grade progression than volume progression.
|
|
|
|
|
|
| Decipher Genomic Classifier on Initial Prostate Biopsy is Associated with Gleason Score Upgrading on Final Radical Prostatectomy Pathology
|
| John Sheng, MD
|
| John Sheng discusses the influence of the Decipher genomic classifier on initial prostate biopsy Gleason Score upgrading on final radical prostatectomy pathology. The study, including 888 patients, found that Decipher genomic classifier on biopsy was associated with upgrading on prostatectomy Gleason grade group. This emphasizes the role of genomic classifiers like Decipher in predicting adverse pathology in localized prostate cancer.
|
|
|
|
|
|
| Decipher Genomic Classifier Score on Initial Biopsy is Associated with Progression from Active Surveillance to Treatment in Prostate Cancer
|
| Nimrod S. Barashi, MD |
| Nimrod Barashi discusses the association of the Decipher genomic classifier on initial prostate biopsy with progression from active surveillance to treatment. The study, including 888 patients, reveals that an increased Decipher genomic classifier is an independent predictor of progression to treatment in patients on active surveillance, while multiparametric MRI (PI-RADS) is not associated with progression. |
|
|
|
|
|
|
|
|
|
|
| PSMA PET/CT-Detected Mesorectal Nodal Metastasis in Biochemically Recurrent Prostate Cancer Patients
|
| Rashid K. Sayyid, MD, MSc
|
| Rashid Sayyid presents findings that show that PSMA PET/CT detects mesorectal lymph node metastasis in 11% of prostate cancer patients with biochemical failure. Notably, pT3b disease presence increases odds by 4.31-fold, suggesting alternate drainage routes for cancer cells. The study prompts further exploration of prognosis and drainage mechanisms in mesorectal lymph node metastasis.
|
|
|
|
|
|
| Factors Associated with PSMA Positivity at Low PSA After Radical Prostatectomy
|
| Eric V. Li, MD
|
| Eric Li discusses factors associated with PSMA positivity at low PSA after radical prostatectomy. The study, based on PSMA PET/CT data from post-radical prostatectomy patients, reveals that even at low PSA levels, approximately 40% of men with PSAs <0.2 ng/ml had positive imaging findings concerning recurrence. This suggests that PET-PSMA imaging at low PSAs can be considered in selective individuals to inform salvage therapies.
|
|
|
|
|
|
| FALCON: Gaining Consensus on Focal Therapy for Localized Prostate Cancer
|
| Lara Rodríguez Sánchez, MD, Ph.D.
|
| Lara Rodríguez Sánchez presents the Falcon Project which aims to establish a consensus on focal therapy for prostate cancer. This initiative involves an extensive international consensus, covering patient selection, treatment approach, and follow-up. The Falcon project serves as a comprehensive guide and highlights areas for future research in focal therapy
|
|
|
|
|
|
| SWOG 2210: Neoadjuvant Carboplatin for High-Risk Localized Prostate Cancer with Germline BRCA1/2 Mutations
|
| Heather Cheng, MD, Ph.D.
|
| Heather Cheng presents SWOG 2210 focusing on neoadjuvant carboplatin for localized high-risk prostate cancer with germline BRCA1/2 mutations. The trial aims to evaluate pathologic complete response rates after 12 weeks of neoadjuvant carboplatin followed by radical prostatectomy, offering a potential therapeutic approach for this specific subgroup of patients.
|
|
|
|
|
|
| NePtune - A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations
|
| Rana McKay, MD
|
| Rana McKay presents the NePtune trial focusing on neoadjuvant PARP inhibition plus androgen deprivation therapy followed by radical prostatectomy in patients with unfavorable intermediate- or high-risk prostate cancer with BRCA1/2 gene alterations. The trial aims to assess the efficacy and safety of this approach, providing insights into potential neoadjuvant therapies for patients with specific genomic alterations.
|
|
|
|
|
|
|
